Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Ensovibep in Healthy Volunteers
NCT04870164Phase 1Terminated
- Sponsor
- Molecular Partners AG
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ensovibep in coronavirus disease 2019 (COVID-19) (14 arms), sponsored by Molecular Partners AG. Primary endpoints: Vital Signs: Blood Pressure Systolic and Diastolic, Vital Signs: Heart Rate and 7 more. Started Nov 2020; status: terminated.
02
Drugs
ensovibep
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04870164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870164.